humanized hA19 antibody (Immunomedics)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Namehumanized hA19 antibody (Immunomedics)
Drug Alias Nameanti-CD19 antibodies (Immunomedics)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionB-lymphocyte antigen CD19 inhibitors
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsAutoimmune DiseasesLymphoma, B-CellPrecursor Cell Lymphoblastic Leukemia-Lymphoma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesImmunomedics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesImmunomedics Inc
Active IndicationsN/A
Inactive IndicationsAutoimmune DiseasesLymphoma, B-CellPrecursor Cell Lymphoblastic Leukemia-Lymphoma +[4] 

Other Information

ATC CodeN/A
Related LinksN/A